T. Rowe Price Cuts Tesla from 'Magnificent Seven,' Bets on Healthcare & Utilities

Veteran fund manager David Giroux of T. Rowe Price has made a notable portfolio reallocation, removing electric vehicle manufacturer Tesla from the so-called 'Magnificent Seven' cohort of dominant tech stocks. Giroux's decision reflects a shift in investment strategy, despite his assertion that the broader 'Big Tech' sector is not currently experiencing a bubble. Instead, he highlights compelling value opportunities within the healthcare and utilities sectors. This move by a prominent institutional investor signals a potential re-evaluation of high-growth tech valuations and a search for more defensive or value-oriented plays. Tesla's stock performance has been volatile in recent periods, facing increased competition and questions about its long-term growth trajectory in a rapidly evolving automotive market. Conversely, healthcare and utilities often offer more stable earnings and dividend yields, appealing to investors seeking resilience amid broader market uncertainties or a more diversified exposure. Giroux's comments indicate a nuanced view of the market, distinguishing between overall tech valuations and specific company fundamentals. His fund's rebalancing could influence other institutional investors to scrutinize their own holdings within the 'Magnificent Seven' and consider sectors beyond traditional technology for long-term growth and stability. This portfolio adjustment underscores an ongoing debate about market concentration and the search for sustainable value in a dynamic economic environment.